GSK says faces UK serious fraud investigation
May 27 (Reuters) – GlaxoSmithKline Plc said on Tuesday that Britain’s Serious Fraud Office (SFO) has opened a formal criminal investigation into its commercial practices.
GSK said in a statement that it would cooperate fully with the SFO and was committed to operating its business to the highest ethical standards.
The statement gave no further details about the investigation. (Reporting by Andy Bruce, editing by David Milliken